These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 9329578

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P, Fornier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E.
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [Abstract] [Full Text] [Related]

  • 3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM, Gaarenstroom KN, Korse CM, Van Bunningen BN, Kenemans P.
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W, Hoppe M, Muley T, Drings P.
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer.
    Stieber P, Schmeller N, Schambeck C, Hofmann K, Reiter W, Hasholzner U, Fateh-Moghadam A.
    Anticancer Res; 1996; 16(6B):3793-8. PubMed ID: 9042259
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K.
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [Abstract] [Full Text] [Related]

  • 14. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia.
    Tramonti G, Ferdeghini M, Donadio C, Norpoth M, Annichiarico C, Bianchi R, Bianchi C.
    Cancer Detect Prev; 2000 Aug; 24(1):86-90. PubMed ID: 10757127
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
    Boher JM, Pujol JL, Grenier J, Daurès JP.
    Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. CYFRA 21-1 serum analysis in patients with esophageal cancer.
    Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ.
    Clin Cancer Res; 2000 Nov; 6(11):4249-52. PubMed ID: 11106239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.